Clinical trials: Neck Cancer
Cervical Cancer
HPV DNA Testing Through Mobile Mammography Unit
Invasive cervical cancer incidence and mortality can be dramatically reduced through early detection and treatment, but many women do not complete screening at recommended intervals.
- Trial name
- NCT03551028
- Testing
- HPV self collection
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Oral Cavity Carcinoma, Oral Intraepithelial Neoplasia
Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia
This randomized phase II trial studies how well pembrolizumab works in treating patients with high risk oral intraepithelial neoplasia.
- Trial name
- NCT02882282
- Testing
- Laboratory Biomarker Analysis, Patient Observation, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Oral Mucositis, Oral Cancer
Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis
The purpose of this study is to determine the effects of a novel oral care protocol on the severity and pain of oral mucositis in patients receiving radiation and/or chemotherapy for head and neck cancers.
- Trial name
- OMDP (NCT02608879)
- Testing
- Oral Mucosa Deterging and Periodontal Debridement (OMDP), Standard of Care Oral Hygiene Instructions, Dental scaling, ultrasonic
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- NYU Langone Health
Differentiated Thyroid Cancer
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid…
- Trial name
- NCT03690388
- Testing
- Cabozantinib
- Where
- 164 sites in United States, Argentina and 23 more
- Volunteers
- 187 people
- Sponsor
- Exelixis
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Head and Neck Cancer, Oral Mucositis
Commensal Oral Microbiota in Head and Neck Cancer
The ARMOR Trial will test the efficacy of an oral care protocol to treat oral mucositis (OM) in patients receiving radiation (RT) or chemoradiation (chemoRT) for head and neck cancer.
- Trial name
- ARMOR (NCT03843554)
- Testing
- Standard of Care Oral Hygiene, Oral mucosal deterging and dental prophylaxis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Pennsylvania
Head and Neck Cancer
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00248560
- Testing
- docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Recurrent Nasopharynx Carcinoma
Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma
This is a pilot study to evaluate the response rates for patients undergoing high dose conditioning chemotherapy using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of…
- Trial name
- NCT02137096
- Testing
- Etoposide phosphate, Carboplatin, Ifosfamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Florida
Head and Neck Cancer
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
- Trial name
- CheckMate 651 (NCT02741570)
- Testing
- Nivolumab, Ipilimumab, Cetuximab/Erbitux
- Where
- 133 sites in United States, Australia and 16 more
- Volunteers
- 947 people
- Sponsor
- Bristol-Myers Squibb
HPV16 Associated Cervical Cancer
Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer
This study will be looking at what dose of the TA-CIN vaccine is safe and effective in patients with a history of HPV16-associated cervical cancer.
- Trial name
- NCT02405221
- Testing
- TA-CIN (arm), TA-CIN (thigh)
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
This phase III trial compares the effect of adding nivolumab to the usual chemotherapy (cisplatin or carboplatin with gemcitabine) versus standard chemotherapy alone in treating patients with nasopharyngeal cancer that has come…
- Conditions
- Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Metastatic Nasopharyngeal Nonkeratinizing Carcinoma, Metastatic Nasopharyngeal Undifferentiated Carcinoma
- Trial name
- NCT04458909
- Testing
- Carboplatin, Cisplatin, Gemcitabine
- Where
- 325 sites in United States, Canada and 2 more
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Precancerous Condition
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or…
- Trial name
- NCT01302834
- Testing
- cetuximab, cisplatin, IMRT
- Where
- 185 sites in United States, Canada
- Volunteers
- 987 people
- Sponsor
- Radiation Therapy Oncology Group
Oropharyngeal Cancer
TraceIT Tissue Marker to Mark the Primary Resection Bed Margins of Oropharyngeal Cancers
The purpose of this research study is to look at how using an injectable marker called TraceIT can help with the radiation treatment planning process.
- Trial name
- NCT03713021
- Testing
- TraceIT Tissue Marker
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Esophageal Squamous Cell Carcinoma
Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus
This study will evaluate the safety and feasibility of preoperative immune checkpoint therapy with concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
- Trial name
- PALACE-1 (NCT03792347)
- Testing
- Pembrolizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hecheng Li M.D., Ph.D
Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
This phase II trial studies the effect of chemoradiation and pembrolizumab followed by pembrolizumab and lenvatinib before surgery in treating patients with esophageal or esophageal/gastroesophageal junction cancer that has not…
- Conditions
- Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT04929392
- Testing
- Carboplatin, Endoscopic Biopsy, External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16
HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts
Primary, Secondary, and Exploratory Objective(s): Primary objective: To evaluate the effect of interventions on 1st dose uptake of HPV vaccine.
- Conditions
- Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6
- Trial name
- NCT02551887
- Testing
- Automated Reminder, Automated Reminder Plus Script
- Volunteers
- 647 people
- Sponsor
- Regenstrief Institute, Inc.
Head and Neck Cancer
Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
The purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of care treatment for head and neck cancer.
- Trial name
- NCT02641093
- Testing
- Pembrolizumab, Surgery, Radiation Therapy
- Where
- 6 sites in United States
- Volunteers
- 96 people
- Sponsor
- Trisha Wise-Draper
Head and Neck Cancer, Squamous Cell Carcinoma
Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy
The purpose of this study is to investigate the safety of zalutumumab in combination with radiotherapy as the treatment of patients with head and neck cancer who are not eligible for platinum based chemotherapy.
- Trial name
- NCT00707655
- Testing
- Zalutumumab
- Where
- 8 sites in Belgium, France and 1 more
- Volunteers
- 8 people
- Sponsor
- Genmab
Infections, Papillomavirus
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
This extension study is designed to assess the safety of GSK Biological's human papillomavirus (HPV) vaccine GSK580299 in female subjects who took part in the primary study NCT00294047 and received the control vaccine in…
- Trial name
- NCT01190189
- Testing
- GSK580299 (Cervarix)
- Where
- 28 sites in United States, Canada
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
This phase II trial is studying how well sunitinib works in treating patients with recurrent and/or metastatic head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00387335
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.